Abstract
Abstract
Background
This paper explores the extent to which the implementation and evaluation of a collaborative care model of face-to-face service delivery for people with severe mental illness was viable during the first UK lockdown associated with COVID-19. The PARTNERS2 cluster randomised controlled trial and process evaluation were co-designed with service users and carers. The aim of this paper is to explore whether digital adaptation of the PARTNERS model for people with severe mental illness during the COVID-19 lockdown was equitable, in terms of fostering collaboration and trust in a vulnerable population.
Results
We collected qualitative data from multiple sources during lockdown and subsequently constructed case-studies of participating secondary care workers. We adopted Bauman’s notions of liquid modernity to inform our analysis, and identified that digital adaptation during lockdown was only successful where organisational policies, care partner skills and service users’ existing resources were optimal.
Conclusion
PARTNERS2 can be delivered digitally by a care partner to support people with severe mental illness to identify and work towards their goals when existing resources are optimal. However, at a time of increased need, we identified that people who are very unwell and living with limited access to resources and opportunities, remained disenfranchised at great cost.
Trial registration
ISRCTN 95702682, registered 26.10.2017
Funder
National Institute for Health and Care Research
Publisher
Springer Science and Business Media LLC
Reference54 articles.
1. Thornicroft G. Shunned: Discrimination against people with mental illness, vol. 301. Oxford: Oxford University Press; 2006.
2. British Medical Association. Health at a price: Reducing the impact of poverty: A briefing from the board of science. 2017. bma.org.uk
3. Plappert et al. Evaluation of a primary care-based collaborative care model (PARTNERS2) for people with diagnoses of schizophrenia, bipolar, or other psychoses: study protocol for a cluster randomised controlled trial. BJGP Open. 2021;5(3):BJGPO.2021.0033.
4. Morant N, Azam K, Johnson S, Moncrieff J. The least worst option: user experiences of antipsychotic medication and lack of involvement in medication decisions in a UK community sample. J Ment Health. 2018;27(4):322–8.
5. Hayes J, Marston L, Walters K, King M, Osborn D. Mortality gap for people with bipolar disorder and schizophrenia: UK-based cohort study 2000–2014. Br J Psychiatry. 2017;211(3):175–81.